Virtual Library
Start Your Search
J. Giner Joaquin
Author of
-
+
P3.03 - Poster Session with Presenters Present (ID 473)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.03-055 - Results of Second-Line Chemotherapy in Pleural Mesothelioma: A Single-Centre, Retrospective Study (ID 5860)
14:30 - 14:30 | Author(s): J. Giner Joaquin
- Abstract
Background:
Currently there is no standard treatment for patients with malignant mesothelioma progressing to first-line chemotherapy. Data is available on combined chemotherapy with platinum plus pemetrexed / ralitrexed / gemcitabine depending on previous treatment and on monotherapy treatment.
Methods:
We included 33 patients from a single centre treated with second-line chemotherapy between May 2002 and March 2016 and described their epidemiological, pathological, therapeutic and survival characteristics.
Results:
The median age was 68.2 years (44-84), 69.7% male and 69.7% had been exposed to asbestos. The origin was: 93.9% pleural, pericardial 6.1%. Histology was: 60.6% epithelioid, biphasic 9.1%, 6.1% sarcomatoid and 24.2% unknown. The distribution of clinical stages was: I and II (30.3%), III and IV (48.5%). Palliative pleurodesis was performed in 69.7%. A total of 63.6% had ECOG (0-1) and ECOG (2) 6.1%. The response rate in the first line was 57.6% and 30% of stabilizations. The treatments administered were: platinum + gemcitabine (69.7%), platinum + pemetrexed (12.1%), vinorelbine (9.1%), oxaliplatin + ralitrexed (6.1%), gemcitabine + irinotecan 1p (3%). Retreatment with pemetrexed was administered in 12.1%. Patients received a median of 4 cycles (1-19) of treatment. The response rate was 30.3%, with 21.2% of stabilizations. The treatment was stopped for progression in 48.5% and secondary to toxicity in 27.3%. At the moment of progression ECOG was (0-1) 66.7% and (2-3) 15.2%. Third-line treatment was administered to 39.4%. Progression-free survival was 4.3 months (95% CI 2.303-6.288) with no significant differences according to treatment received (p = 0.064) or PS (p = 0.345). The median overall survival was 9.7 months (95% CI 6.670-12.740). The median time from the last administration of chemotherapy to death was 6.8 months (95% CI 2240-6288).
Conclusion:
In our experience, second-line chemotherapy in malignant mesothelioma is feasible, with a clinical benefit and a response rate that allows third-line treatment to be administered to a non-negligible percentage of patients.
